ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Hydrochloric Acid → 3-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide 3-(4-chloro-2-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide

HRID 1524403
印刷

反応式

HRID 1524403 の反応式
[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[C:16]3[C:11](=[CH:12][C:13]([S:17]([N:20](CC4C=CC(OC)=CC=4OC)[C:21]4[S:25][N:24]=[CH:23][N:22]=4)(=[O:19])=[O:18])=[CH:14][CH:15]=3)[NH:10][CH:9]=2)=[C:4]([C:37]2[N:41]([CH3:42])[N:40]=[CH:39][CH:38]=2)[CH:3]=1.Cl.[CH3:44]O>C(Cl)Cl>[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[C:16]3[C:11](=[CH:12][C:13]([S:17]([NH:20][C:21]4[S:25][N:24]=[CH:23][N:22]=4)(=[O:18])=[O:19])=[CH:14][CH:15]=3)[NH:10][CH:9]=2)=[C:4]([C:37]2[CH:38]=[CH:39][N:40]([CH3:44])[N:41]=2)[CH:3]=1.[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[C:16]3[C:11](=[CH:12][C:13]([S:17]([NH:20][C:21]4[S:25][N:24]=[CH:23][N:22]=4)(=[O:19])=[O:18])=[CH:14][CH:15]=3)[NH:10][CH:9]=2)=[C:4]([C:37]2[N:41]([CH3:42])[N:40]=[CH:39][CH:38]=2)[CH:3]=1
参加物実験手順後処理出典と根拠反応ノート

参加物

5

反応物 3

HCID 313Hydrochloric AcidHCID 887MethanolHCID 712592093-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenyl)-N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide2 回

生成物 1

HCID 894076863-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide 3-(4-chloro-2-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide収率 90%

試薬・触媒・溶媒 1

HCID 6344Dichloromethane溶媒

実験手順

A vial was charged with 3-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenyl)-N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide (Intermediate A) (28.44 mg, 0.046 mmol) in methanol (0.5 mL). Hydrogen chloride (4M in 1,4-dioxane) (114 μl, 0.458 mmol) was added, and the resulting mixture was stirred for 30 min. The mixture was diluted with DCM and concentrated in vacuo. The residue was suspended in MeOH, then filtered through Celite® (diatomaceous earth). The filtrate was concentrated, and the residue was dissolved in methanol and loaded onto a 500 mg SCX-2 ion exchange column. The column was eluted with methanol, then with a solution of 2N ammonia in methanol. The basic fractions were concentrated to give 3-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide 3-(4-chloro-2-(1-methyl-1H-pyrazol-3-yl)phenyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-6-sulfonamide (19.36 mg, 0.041 mmol, 90% yield) as a light-yellow solid. 1H NMR (400 MHz, DMSO-d6) δ=11.57 (br. s., 1 H), 8.05 (s, 1 H), 7.85 (dd, J=0.5, 1.6 Hz, 1 H), 7.71-7.58 (m, 2 H), 7.54 (d, J=8.5 Hz, 1 H), 7.49 (d, J=2.2 Hz, 1 H), 7.43-7.33 (m, 2 H), 7.23-7.04 (m, 1 H), 6.93 (d, J=2.6 Hz, 1 H), 6.30 (d, J=1.9 Hz, 1 H), 3.19 (br. s., 1 H). m/z (ESI) 471.0 (M+H)+.

後処理

  1. concentrationconcentrated in vacuo
  2. filtrationfiltered through Celite® (diatomaceous earth)
  3. concentrationThe filtrate was concentrated
  4. dissolutionthe residue was dissolved in methanol
  5. washThe column was eluted with methanol
  6. concentrationThe basic fractions were concentrated

出典と根拠

ORDレコード
ord-e663413906b146a29354bce62e0c6ac0
出典データセット
uspto-grants-2015_07
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US09079902B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート